Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
US Approval Decision Expected By 5 August
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
